Avivagen Stock Forecast, Price & News

+0.02 (+5.41 %)
(As of 07/23/2021 05:41 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,500 shs
Average Volume110,091 shs
Market CapitalizationC$22.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VIV News and Ratings via Email

Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter.

About Avivagen

Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. It has operations in Mexico and Latin America. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen May 2012. Avivagen Inc. was founded in 2005 and is headquartered in Ottawa, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.66 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Avivagen (CVE:VIV) Frequently Asked Questions

What stocks does MarketBeat like better than Avivagen?

Wall Street analysts have given Avivagen a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avivagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avivagen's next earnings date?

Avivagen is scheduled to release its next quarterly earnings announcement on Wednesday, September 1st 2021.
View our earnings forecast for Avivagen

How were Avivagen's earnings last quarter?

Avivagen Inc. (CVE:VIV) posted its earnings results on Wednesday, June, 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.02. The firm earned $0.16 million during the quarter, compared to analysts' expectations of $0.93 million.
View Avivagen's earnings history

How has Avivagen's stock price been impacted by Coronavirus (COVID-19)?

Avivagen's stock was trading at C$0.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VIV shares have decreased by 35.0% and is now trading at C$0.39.
View which stocks have been most impacted by COVID-19

Who are Avivagen's key executives?

Avivagen's management team includes the following people:
  • Mr. G. F. Kym Anthony, CEO, Pres & Director (Age 65, Pay $362.43k)
  • Dr. Graham Burton, Co-Founder, Chief Scientific Officer & Director
  • Mr. Christopher Boland, Chief Financial Officer
  • Mr. Drew Basek, Director of Investor Relations
  • Ms. Tracy Gillett BVSC, Marketing Mang.

Who are some of Avivagen's key competitors?

What other stocks do shareholders of Avivagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avivagen investors own include (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX), Applied Genetic Technologies (AGTC), The AES (AES) and AbbVie (ABBV).

What is Avivagen's stock symbol?

Avivagen trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VIV."

How do I buy shares of Avivagen?

Shares of VIV and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Avivagen's stock price today?

One share of VIV stock can currently be purchased for approximately C$0.39.

How much money does Avivagen make?

Avivagen has a market capitalization of C$22.21 million and generates C$1.32 million in revenue each year.

How many employees does Avivagen have?

Avivagen employs 14 workers across the globe.

What is Avivagen's official website?

The official website for Avivagen is

How can I contact Avivagen?

The company can be reached via phone at 613-949-8164.

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.